IDH1 and acute myeloid leukemia: An open-label, Non-randomized, Multicenter phase I study to determine the maximum tolerated and / or recommended phase II dose of oral mutant IDH1 (mIDH1) inhibitor BAY1436032 and to characterize its safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and preliminary clinical efficacy in patients with mIDH1-R132X advanced acute myeloid leukemia (AML)